Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.43
-5.6%
$1.35
$0.87
$6.78
$142.49M0.74836,349 shs164,796 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$16.65
-0.9%
$15.45
$9.57
$30.41
$2.29B0.931.55 million shs860,951 shs
The Boeing Company stock logo
BA
Boeing
$216.92
+0.5%
$202.13
$128.88
$218.80
$163.61B1.419.47 million shs2.85 million shs
Citigroup Inc. stock logo
C
Citigroup
$87.37
-1.5%
$76.63
$53.51
$88.82
$163.12B1.3414.63 million shs7.52 million shs
Tesla, Inc. stock logo
TSLA
Tesla
$292.34
-7.3%
$320.93
$182.00
$488.54
$941.94B2.39100.94 million shs101.19 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
0.00%-0.34%-1.01%+46.04%-66.40%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.00%+4.35%-0.18%+63.71%-34.38%
The Boeing Company stock logo
BA
Boeing
0.00%+0.56%+2.24%+55.41%+16.73%
Citigroup Inc. stock logo
C
Citigroup
0.00%+5.05%+13.22%+50.87%+38.48%
Tesla, Inc. stock logo
TSLA
Tesla
0.00%-3.11%+6.24%+34.41%+24.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
3.8299 of 5 stars
3.13.00.04.51.12.50.0
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.7712 of 5 stars
3.42.00.03.42.02.50.0
The Boeing Company stock logo
BA
Boeing
3.2721 of 5 stars
2.44.00.00.02.72.50.6
Citigroup Inc. stock logo
C
Citigroup
4.9174 of 5 stars
2.33.02.52.63.32.54.4
Tesla, Inc. stock logo
TSLA
Tesla
4.4255 of 5 stars
2.13.00.03.52.45.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00180.70% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71162.63% Upside
The Boeing Company stock logo
BA
Boeing
2.72
Moderate Buy$215.77-0.53% Downside
Citigroup Inc. stock logo
C
Citigroup
2.69
Moderate Buy$85.43-2.21% Downside
Tesla, Inc. stock logo
TSLA
Tesla
2.24
Hold$301.603.16% Upside

Current Analyst Ratings Breakdown

Latest TSLA, ARWR, ALEC, C, and BA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Citigroup Inc. stock logo
C
Citigroup
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/7/2025
Citigroup Inc. stock logo
C
Citigroup
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$77.00
7/7/2025
Tesla, Inc. stock logo
TSLA
Tesla
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
7/3/2025
Citigroup Inc. stock logo
C
Citigroup
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$94.00 ➝ $103.00
7/3/2025
Tesla, Inc. stock logo
TSLA
Tesla
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$285.00 ➝ $315.00
7/3/2025
Tesla, Inc. stock logo
TSLA
Tesla
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingReduce ➝ Reduce$120.00
7/2/2025
Citigroup Inc. stock logo
C
Citigroup
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $96.00
7/2/2025
Citigroup Inc. stock logo
C
Citigroup
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$76.00 ➝ $77.00
7/1/2025
Tesla, Inc. stock logo
TSLA
Tesla
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$500.00
6/30/2025
Tesla, Inc. stock logo
TSLA
Tesla
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$290.00
6/30/2025
Tesla, Inc. stock logo
TSLA
Tesla
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$303.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.42N/AN/A$1.29 per share1.10
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M647.51N/AN/A$1.54 per share10.81
The Boeing Company stock logo
BA
Boeing
$66.52B2.46N/AN/A($5.23) per share-41.48
Citigroup Inc. stock logo
C
Citigroup
$81.68B2.00$8.85 per share9.87$101.26 per share0.86
Tesla, Inc. stock logo
TSLA
Tesla
$95.72B9.84$3.59 per share81.41$22.89 per share12.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/A19.75N/A-45.33%-12.49%8/6/2025 (Estimated)
The Boeing Company stock logo
BA
Boeing
-$11.82B-$17.92N/A80.64N/A-16.58%N/A-8.57%7/30/2025 (Estimated)
Citigroup Inc. stock logo
C
Citigroup
$12.68B$6.3313.809.240.697.95%6.94%0.55%7/15/2025 (Estimated)
Tesla, Inc. stock logo
TSLA
Tesla
$7.13B$1.82160.6886.249.176.66%9.02%5.39%7/22/2025 (Estimated)

Latest TSLA, ARWR, ALEC, C, and BA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
The Boeing Company stock logo
BA
Boeing
-$0.92N/AN/AN/A$20.13 billionN/A
7/22/2025Q2 2025
Tesla, Inc. stock logo
TSLA
Tesla
$0.43N/AN/AN/A$23.18 billionN/A
7/15/2025Q2 2025
Citigroup Inc. stock logo
C
Citigroup
$1.73N/AN/AN/A$20.75 billionN/A
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
4/23/2025Q1 2025
The Boeing Company stock logo
BA
Boeing
-$1.39-$0.49+$0.90-$0.16$19.57 billion$19.50 billion
4/22/2025Q1 2025
Tesla, Inc. stock logo
TSLA
Tesla
$0.53$0.27-$0.26$0.12$22.93 billion$19.34 billion
4/15/2025Q1 2025
Citigroup Inc. stock logo
C
Citigroup
$1.84$1.96+$0.12$1.96$21.34 billion$21.60 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
The Boeing Company stock logo
BA
Boeing
N/AN/AN/AN/AN/A
Citigroup Inc. stock logo
C
Citigroup
$2.242.56%N/A35.39%2 Years
Tesla, Inc. stock logo
TSLA
Tesla
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.31
5.15
5.15
The Boeing Company stock logo
BA
Boeing
N/A
1.23
0.37
Citigroup Inc. stock logo
C
Citigroup
1.52
0.98
0.98
Tesla, Inc. stock logo
TSLA
Tesla
0.07
2.00
1.54

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
The Boeing Company stock logo
BA
Boeing
64.82%
Citigroup Inc. stock logo
C
Citigroup
71.72%
Tesla, Inc. stock logo
TSLA
Tesla
66.20%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.10%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
4.30%
The Boeing Company stock logo
BA
Boeing
0.09%
Citigroup Inc. stock logo
C
Citigroup
0.08%
Tesla, Inc. stock logo
TSLA
Tesla
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million132.16 millionOptionable
The Boeing Company stock logo
BA
Boeing
172,000754.01 million753.33 millionOptionable
Citigroup Inc. stock logo
C
Citigroup
239,0001.87 billion1.87 billionOptionable
Tesla, Inc. stock logo
TSLA
Tesla
125,6653.22 billion2.55 billionOptionable

Recent News About These Companies

Options Bears Cheer Another Tesla Stock Setback
Tesla Stock Breakdown: Why Another 20% Drop is Next
Top Stock Movers Now: Tesla, Shell, Uber, and More
Best Automotive Stocks To Follow Now - July 7th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alector stock logo

Alector NASDAQ:ALEC

$1.42 -0.09 (-5.63%)
As of 02:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.64 -0.15 (-0.86%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Boeing stock logo

Boeing NYSE:BA

$216.92 +1.00 (+0.46%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight and launch systems, and services worldwide. The company operates through Commercial Airplanes; Defense, Space & Security; and Global Services segments. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for passenger and cargo requirements, as well as provides fleet support services. The Defense, Space & Security segment engages in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems; strategic defense and intelligence systems, which include strategic missile and defense systems, command, control, communications, computers, intelligence, surveillance and reconnaissance, cyber and information solutions, and intelligence systems; and satellite systems, such as government and commercial satellites, and space exploration. The Global Services segment offers products and services, including supply chain and logistics management, engineering, maintenance and modifications, upgrades and conversions, spare parts, pilot and maintenance training systems and services, technical and maintenance documents, and data analytics and digital services to commercial and defense customers. The Boeing Company was incorporated in 1916 and is based in Arlington, Virginia.

Citigroup stock logo

Citigroup NYSE:C

$87.36 -1.36 (-1.53%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Citigroup Inc., a diversified financial service holding company, provides various financial product and services to consumers, corporations, governments, and institutions worldwide. It operates through five segments: Services, Markets, Banking, U.S. Personal Banking, and Wealth. The Services segment includes Treasury and Trade Solutions, which provides cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations; and Securities Services, such as cross-border support for clients, local market expertise, post-trade technologies, data solutions, and various securities services solutions. The Markets segment offers sales and trading services for equities, foreign exchange, rates, spread products, and commodities to corporate, institutional, and public sector clients; and market-making services, including asset classes, risk management solutions, financing, prime brokerage, research, securities clearing, and settlement. The banking segment includes investment banking; advisory services related to mergers and acquisitions, divestitures, restructurings, and corporate defense activities; and corporate lending, which includes corporate and commercial banking. The U.S. Personal Banking segment provides co-branded cards and retail banking services. The Wealth segment provides financial services to high-net-worth clients through banking, lending, mortgages, investment, custody, and trust product offerings; and to professional industries, including law firms, consulting groups, accounting, and asset management. The company was founded in 1812 and is headquartered in New York, New York.

Tesla stock logo

Tesla NASDAQ:TSLA

$292.34 -23.01 (-7.30%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. The company operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty after-sales vehicle, used vehicles, body shop and parts, supercharging, retail merchandise, and vehicle insurance services. This segment also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. The Energy Generation and Storage segment engages in the design, manufacture, installation, sale, and leasing of solar energy generation and energy storage products, and related services to residential, commercial, and industrial customers and utilities through its website, stores, and galleries, as well as through a network of channel partners; and provision of service and repairs to its energy product customers, including under warranty, as well as various financing options to its solar customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was incorporated in 2003 and is headquartered in Austin, Texas.